1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7H-purine-2,6-dione, also known as **pentoxifylline**, is a medication that has been used for several decades to treat a variety of medical conditions.
Here's a breakdown of its structure, function, and importance in research:
**Structure:**
* **Pentoxifylline** is a synthetic compound belonging to the methylxanthine class.
* It has a purine ring structure, similar to caffeine and theophylline.
* The 1,3-dimethyl part refers to two methyl groups attached to the purine ring at positions 1 and 3.
* The 8-(4-phenyl-1-piperazinyl) part indicates a piperazine ring with a phenyl group attached at position 4, and this entire group is linked to the purine ring at position 8.
* The 7H-purine-2,6-dione part specifies the presence of two ketone groups at positions 2 and 6 of the purine ring.
**Function:**
Pentoxifylline has multiple pharmacological actions:
* **Vasodilation:** It relaxes blood vessels, improving blood flow. This effect is primarily mediated by its inhibition of phosphodiesterase, an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a signaling molecule that promotes vasodilation.
* **Anti-inflammatory:** Pentoxifylline reduces inflammation by inhibiting the production of inflammatory mediators like tumor necrosis factor-alpha (TNF-α).
* **Anti-platelet:** It reduces platelet aggregation, making the blood less prone to clotting.
* **Antioxidant:** Pentoxifylline can protect cells from damage caused by free radicals.
**Importance in Research:**
Pentoxifylline is of ongoing research interest for several reasons:
* **Treatment of Peripheral Artery Disease (PAD):** It is commonly used to improve blood flow and reduce symptoms in patients with PAD. Studies continue to explore its effectiveness in treating PAD and its potential role in preventing complications.
* **Neuroprotection:** Pentoxifylline has been shown to protect neurons from damage in various models of stroke and neurodegenerative diseases. Research focuses on its potential therapeutic benefits for these conditions.
* **Cancer Treatment:** Pentoxifylline has demonstrated anti-cancer effects in several studies, and its mechanisms of action are being investigated.
* **Anti-Inflammatory Applications:** Its anti-inflammatory properties make it a potential treatment for conditions such as inflammatory bowel disease, arthritis, and autoimmune disorders.
**Current Research:**
* **Dosage and Administration:** Research is ongoing to optimize the dosage and delivery methods of pentoxifylline for various conditions.
* **Combination Therapies:** Studies are exploring the effectiveness of pentoxifylline in combination with other drugs for treating complex diseases.
* **Mechanism of Action:** Scientists are investigating the specific molecular mechanisms underlying pentoxifylline's various pharmacological effects to further understand its therapeutic potential.
In summary, 1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7H-purine-2,6-dione (pentoxifylline) is a multifaceted drug with significant research implications. Its potential to treat a wide range of diseases continues to be investigated, making it a valuable subject of ongoing scientific inquiry.
ID Source | ID |
---|---|
PubMed CID | 949903 |
CHEMBL ID | 1731509 |
CHEBI ID | 108226 |
Synonym |
---|
smr000294930 |
1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-3,7-dihydro-1h-purine-2,6-dione |
MLS000664957 |
STK164790 |
1,3-dimethyl-8-(4-phenylpiperazin-1-yl)-3,7-dihydro-1h-purine-2,6-dione |
OPREA1_746113 |
CHEBI:108226 |
1,3-dimethyl-8-(4-phenylpiperazin-1-yl)-7h-purine-2,6-dione |
AKOS002317647 |
HMS2702C08 |
CCG-22350 |
AB00358981-08 |
CHEMBL1731509 |
1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7h-purine-2,6-dione |
Q27186920 |
NCGC00292511-01 |
1,3-dimethyl-8-(4-phenylpiperazino)-3,7-dihydro-1h-purine-2,6-dione |
Class | Description |
---|---|
piperazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 44.6684 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5750 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
TDP1 protein | Homo sapiens (human) | Potency | 23.1093 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
67.9K protein | Vaccinia virus | Potency | 5.6234 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 79.4328 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 28.1838 | 3.9811 | 46.7448 | 112.2020 | AID720711 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |